{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:57:44Z","timestamp":1790323064826,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1106,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"MSD, Denmark ApS"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41379-019-0339-0","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:04:39Z","timestamp":1565003079000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population"],"prefix":"10.1016","volume":"33","author":[{"given":"Birgit Guldhammer","family":"Skov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Bird","family":"R\u00f8rvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Hartvig Lindk\u00e6r","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-019-0339-0_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0339-0_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0339-0_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1038\/s41379-019-0339-0_bib4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-019-0339-0_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1038\/s41379-019-0339-0_bib6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41379-018-0173-9","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features","volume":"32","author":"Ye","year":"2018","journal-title":"Modern Pathology"},{"key":"10.1038\/s41379-019-0339-0_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CJI.0000000000000249","article-title":"Clinicopathologic correlation with expression of PD-L1 on both tumor cells and tumor-infiltrating immune cells in patients with non-small cell lung cancer","volume":"42","author":"Song","year":"2019","journal-title":"J Immunother"},{"key":"10.1038\/s41379-019-0339-0_bib8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdy126","article-title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","volume":"29","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-019-0339-0_bib9","doi-asserted-by":"crossref","unstructured":"Evans M, O'Sullivan B, Hughes F, Mullis T, Smith M, Trim N, et al. The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 Assay. Pathol Oncol Res. 2018 Sep 17; [Epub ahead of print].","DOI":"10.1007\/s12253-018-0469-6"},{"key":"10.1038\/s41379-019-0339-0_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/apm.12328","article-title":"The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population","volume":"123","author":"Skov","year":"2015","journal-title":"APMIS"},{"key":"10.1038\/s41379-019-0339-0_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAI.0000000000000540","article-title":"Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx","volume":"25","author":"Skov","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-019-0339-0_bib12","doi-asserted-by":"crossref","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243\u201360.","DOI":"10.1097\/JTO.0000000000000630"},{"key":"10.1038\/s41379-019-0339-0_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0339-0_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.21037\/tlcr.2018.06.09","article-title":"Predictive markers for anti-PD-1\/PD-L1 therapy in non-small cell lung cancer-where are we?","volume":"7","author":"Evans","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1038\/s41379-019-0339-0_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-019-0339-0_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jtho.2016.10.015","article-title":"Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases","volume":"12","author":"Uruga","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-019-0339-0_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdy545","article-title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-019-0339-0_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncy.21977","article-title":"Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients","volume":"126","author":"Ilie","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1038\/s41379-019-0339-0_bib19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncy.21937","article-title":"PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens","volume":"125","author":"Heymann","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1038\/s41379-019-0339-0_bib20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncy.21987","article-title":"Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations","volume":"126","author":"Noll","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1038\/s41379-019-0339-0_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jasc.2018.02.003","article-title":"PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?","volume":"7","author":"Torous","year":"2018","journal-title":"J Am Soc Cytopathol"},{"issue":"P1","key":"10.1038\/s41379-019-0339-0_bib22","first-page":"04","article-title":"Comparison of clinical response to checkpoint inhibitors in advanced NSCLC with high PD-L1 expression tested on cytology versus biopsy samples","volume":"13","author":"Guo","year":"2018","journal-title":"J Am Soc Cyctopathol"},{"key":"10.1038\/s41379-019-0339-0_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ajcp\/aqy164","article-title":"Assessment of programmed death-ligand 1 (PD-L1) immunohistochemical expression on cytology specimens in non-small cell lung carcinoma","volume":"151","author":"Hernandez","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-019-0339-0_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2018.10.017","article-title":"Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer","volume":"126","author":"Capizzi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-019-0339-0_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncy.21973","article-title":"Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas","volume":"126","author":"Russell-Goldman","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1038\/s41379-019-0339-0_bib26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/cyt.12605","article-title":"Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas","volume":"29","author":"Jain","year":"2018","journal-title":"Cytopathology"},{"key":"10.1038\/s41379-019-0339-0_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cllc.2015.03.008","article-title":"Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non\u2013small-cell lung cancer","volume":"16","author":"Kitazono","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1038\/s41379-019-0339-0_bib28","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-019-0339-0_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-019-0339-0_bib30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/his.13148","article-title":"The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking","volume":"70","author":"Skov","year":"2017","journal-title":"Histopathology"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0339-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:42:17Z","timestamp":1760229737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222009504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0893395222009504"],"URL":"https:\/\/doi.org\/10.1038\/s41379-019-0339-0","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-019-0339-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}